Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS) - Summary - MDSpire

Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS)

  • By

  • Sundas Ejaz Maqsood

  • John William Posnett

  • Mohamed Elalfy

  • June 4, 2026

  • 0 min

Share

Objective:

To retrospectively assess the clinical outcomes, treatment burden, and direct economic costs associated with the management of persistent corneal epithelial defects (PED) at two major NHS hospitals.

Key Findings:
  • Persistent corneal epithelial defects (PED) require multifactorial treatment approaches.
  • The study aimed to characterize the aetiology, treatment pathways, and clinical resolution rates of PED.
  • There is a lack of real-world data on the treatment burden and costs associated with PED management within the NHS.
Interpretation:

Limitations:
  • The study is retrospective and may be subject to biases inherent in such designs.
  • Data were collected from only two NHS centres, which may limit generalizability.
Conclusion:

Original Source(s)

Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS)

  • by Sundas Ejaz Maqsood, John William Posnett, Mohamed Elalfy

  • June 4, 2026

Related Content

Retinal Imaging AI May Flag Brain Health Risk

Authors said AI-driven retinal screening still lacks evidence that it improves patient outcomes.

One hotspot RB1 mutation disrupt RB1 function founded in a Chinese patient

Association between dry eye and myopia in schoolchildren: current evidence and possible mechanisms